CAR-T Cell Potency: from Structural Elements to Vector Backbone Components

Overview

Journal Biomark Res

Publisher Biomed Central

Date 2022 Sep 19

PMID 36123710

Authors

Marzieh Mazinani

Fatemeh Rahbarizadeh

Affiliations

Soon will be listed here.

Abstract

Chimeric antigen receptor (CAR) T cell therapy, in which a patient's own T lymphocytes are engineered to recognize and kill cancer cells, has achieved remarkable success in some hematological malignancies in preclinical and clinical trials, resulting in six FDA-approved CAR-T products currently available in the market. Once equipped with a CAR construct, T cells act as living drugs and recognize and eliminate the target tumor cells in an MHC-independent manner. In this review, we first described all structural modular of CAR in detail, focusing on more recent findings. We then pointed out behind-the-scene elements contributing to CAR expression and reviewed how CAR expression can be drastically affected by the elements embedded in the viral vector backbone.

Citing Articles

Advances in engineered T cell immunotherapy for autoimmune and other non-oncological diseases.

Huang Q, Zhu X, Zhang Y Biomark Res. 2025; 13(1):23.

PMID: 39901288 PMC: 11792665. DOI: 10.1186/s40364-025-00736-8.

From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy.

Pinto E, Lione L, Compagnone M, Paccagnella M, Salvatori E, Greco M J Transl Med. 2025; 23(1):10.

PMID: 39755643 PMC: 11700462. DOI: 10.1186/s12967-024-06052-3.

Engineering a controllable and reversible switch for CAR-based cellular immunotherapies via a genetic code expansion system.

Liu Y, An L, Wang X, Dai Y, Zhang C, Wen Q J Hematol Oncol. 2024; 17(1):122.

PMID: 39696585 PMC: 11657976. DOI: 10.1186/s13045-024-01648-0.

First-in-class transactivator-free, doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B cell lymphomas.

Justicia-Lirio P, Tristan-Manzano M, Maldonado-Perez N, Barbero-Jimenez C, Cortijo-Gutierrez M, Pavlovic K Mol Ther Nucleic Acids. 2024; 35(4):102308.

PMID: 39640015 PMC: 11617245. DOI: 10.1016/j.omtn.2024.102308.

The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances.

Yao P, Liu Y, Huang G, Hao L, Wang R Exp Hematol Oncol. 2024; 13(1):118.

PMID: 39633491 PMC: 11616395. DOI: 10.1186/s40164-024-00583-7.

References

Guedan S, Posey Jr A, Shaw C, Wing A, Da T, Patel P . Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight. 2018; 3(1). PMC: 5821198. DOI: 10.1172/jci.insight.96976. View

Tipanee J, Samara-Kuko E, Gevaert T, Chuah M, VandenDriessche T . Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy. Mol Ther. 2022; 30(10):3155-3175. PMC: 9552804. DOI: 10.1016/j.ymthe.2022.06.006. View

Schwartz R, Mueller D, Jenkins M, Quill H . T-cell clonal anergy. Cold Spring Harb Symp Quant Biol. 1989; 54 Pt 2:605-10. DOI: 10.1101/sqb.1989.054.01.072. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Coyle A, Lehar S, Lloyd C, Tian J, Delaney T, Manning S . The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity. 2000; 13(1):95-105. DOI: 10.1016/s1074-7613(00)00011-x. View

Alabanza L, Pegues M, Geldres C, Shi V, Wiltzius J, Sievers S . Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains. Mol Ther. 2017; 25(11):2452-2465. PMC: 5675490. DOI: 10.1016/j.ymthe.2017.07.013. View

Gargett T, Yu W, Dotti G, Yvon E, Christo S, Hayball J . GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade. Mol Ther. 2016; 24(6):1135-1149. PMC: 4923328. DOI: 10.1038/mt.2016.63. View

Long A, Haso W, Shern J, Wanhainen K, Murgai M, Ingaramo M . 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015; 21(6):581-90. PMC: 4458184. DOI: 10.1038/nm.3838. View

Zhang A, Sun Y, Du J, Dong Y, Pang H, Ma L . Reducing Hinge Flexibility of CAR-T Cells Prolongs Survival With Low Cytokines Release. Front Immunol. 2021; 12:724211. PMC: 8524077. DOI: 10.3389/fimmu.2021.724211. View

10.

van Rosmalen M, Krom M, Merkx M . Tuning the Flexibility of Glycine-Serine Linkers To Allow Rational Design of Multidomain Proteins. Biochemistry. 2017; 56(50):6565-6574. PMC: 6150656. DOI: 10.1021/acs.biochem.7b00902. View

11.

Wang D, Starr R, Chang W, Aguilar B, Alizadeh D, Wright S . Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma. Sci Transl Med. 2020; 12(533). PMC: 7500824. DOI: 10.1126/scitranslmed.aaw2672. View

12.

Wurtzer S, Goubard A, Mammano F, Saragosti S, Lecossier D, Hance A . Functional central polypurine tract provides downstream protection of the human immunodeficiency virus type 1 genome from editing by APOBEC3G and APOBEC3B. J Virol. 2006; 80(7):3679-83. PMC: 1440420. DOI: 10.1128/JVI.80.7.3679-3683.2006. View

13.

Boomer J, Green J . An enigmatic tail of CD28 signaling. Cold Spring Harb Perspect Biol. 2010; 2(8):a002436. PMC: 2908766. DOI: 10.1101/cshperspect.a002436. View

14.

Ruella M, Barrett D, Kenderian S, Shestova O, Hofmann T, Perazzelli J . Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest. 2016; 126(10):3814-3826. PMC: 5096828. DOI: 10.1172/JCI87366. View

15.

Landoni E, Fuca G, Wang J, Chirasani V, Yao Z, Dukhovlinova E . Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling. Cancer Immunol Res. 2021; 9(4):441-453. PMC: 8137530. DOI: 10.1158/2326-6066.CIR-20-0451. View

16.

Wutti-In Y, Sujjitjoon J, Sawasdee N, Panya A, Kongkla K, Yuti P . Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains. Front Oncol. 2022; 11:802876. PMC: 8804167. DOI: 10.3389/fonc.2021.802876. View

17.

Kochenderfer J, Feldman S, Zhao Y, Xu H, Black M, Morgan R . Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother. 2009; 32(7):689-702. PMC: 2747302. DOI: 10.1097/CJI.0b013e3181ac6138. View

18.

Takahashi C, Mittler R, Vella A . Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol. 1999; 162(9):5037-40. View

19.

Kahlon K, Brown C, Cooper L, Raubitschek A, Forman S, Jensen M . Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 2004; 64(24):9160-6. DOI: 10.1158/0008-5472.CAN-04-0454. View

20.

Ramakrishna S, Highfill S, Walsh Z, Nguyen S, Lei H, Shern J . Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence. Clin Cancer Res. 2019; 25(17):5329-5341. PMC: 8290499. DOI: 10.1158/1078-0432.CCR-18-3784. View